A retrospective observational study on effectiveness of influenza vaccine Supemtek® compared to other vaccines in adults aged 18 years and above in the United Kingdom – a feasibility study

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50746
• EU PAS number:
  EUPAS50220
• Study ID:
  50746
• Official title and acronym:
  A retrospective observational study on effectiveness of influenza vaccine Supemtek® compared to other vaccines in adults aged 18 years and above in the United Kingdom – a feasibility study
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study status:
  Ongoing

Research institutions and networks

Institutions

OPEN Health

Study timelines

Date when funding contract was signed

Actual: 01/02/2022

Study start date

Actual: 01/03/2022

Data analysis start date

Actual: 01/06/2022

Date of final study report

Planned: 31/07/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Sanofi

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable